View Older Stories View More Recent Stories
-
Form 3 Akouos, Inc. For: Jun 25 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AAC
-
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AAC
-
Form 3 Forma Therapeutics Holdi For: Jun 18 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
-
Novavax (NVAX) Raises $200M from Private Placement with RA Capital
-
Novavax to Raise $200 Million from Private Placement with RA Capital
-
Novavax to Raise $200 Million from Private Placement with RA Capital
-
Form SC 13G/A TG THERAPEUTICS, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Everest Medicines Completes US$310 Million Series C Financing
-
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
-
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
-
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes
-
Vor Biopharma Adds to Leadership Team with Appointment of Chief Financial Officer
-
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
-
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Verastem Oncology Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
-
TG Therapeutics (TGTX) Announces $60M in ATM Offering
-
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
-
CANbridge Pharmaceuticals Appoints Acting Chief Scientific Officer
-
Nkarta Therapeutics Appoints Two New Independent Directors
-
Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Vor Biopharma Appoints Dr. Robert Pietrusko as Chief Regulatory and Quality Officer
-
iTeos Therapeutics Closes $125 Million Series B2 Financing
-
iTeos Therapeutics Closes $125 Million Series B2 Financing
-
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
-
Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 3 IMARA Inc. For: Mar 11 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results
-
Form SC 13G Verastem, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Akouos Closes $105 Million Series B Financing
-
Verastem (VSTM) Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors
-
Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors
-
Biotech Veteran Jean-Paul Mangeolle Joins TeraPore Technologies Board of Directors
-
First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication
-
First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication
-
CANbridge Pharmaceuticals Completes US$98 Million Series D Financing
-
Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G RELMADA THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Prevail Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.

